An article by a News Reporter-Staff News Editor at Health and Medicine Business Daily
Read this article by Danielle Ternyila published in Targeted Oncology.
An article by a News Reporter-Staff News Editor at Immunotherapy Daily
Hormone therapies for advanced prostate cancer have greatly prolonged the lives of patients
Enzalutamide has previously been FDA-approved for treatment of metastatic castration-resistant prostate cancer (mCRCP) and non-metastatic castration-resistant prostate cancer (nmCRPC).
A new pilot study concludes that at-home urine tests could make prostate cancer diagnosis shorter, simpler, and possibly even more accurate.